tbuckley/cabot-search huggingface dataset:
Prolonged Zika Virus Viremia during Pregnancy
Authors: Anna Suy, Elena Sulleiro, Carlota Rodó, Élida Vázquez, Cristina Bocanegra, Israel Molina, Juliana Esperalba, María P Sánchez-Seco, Hector Boix, Tomás Pumarola, Elena Carreras
Journal: New England Journal of Medicine (2016)

The presence of Zika virus in the blood may be prolonged during pregnancy. In this letter, Zika virus remained detectable for more than 3 months in a pregnant woman.
Increased Risk of Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV-PTLD) after Anti-Thymocyte Globulin (ATG) Non-Myeloablative (NMA) Conditioning for Umbilical Cord Blood Transplantation (UCBT).
Authors: Claudio G. Brunstein, Daniel J. Weisdorf, Todd DeFor, Jakub Tolar, John E. Wagner
Journal: Blood (2005)
LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis
Authors: Adam Ceroi, David Masson, Anne Roggy, Christophe Roumier, Cécile Chagué, Thierry Gauthier, Laure Philippe, Baptiste Lamarthée, Fanny Angelot-Delettre, Francis Bonnefoy, Sylvain Perruche, Sabeha Biichle, Claude Preudhomme, Elisabeth Macintyre, Laurent Lagrost, Francine Garnache-Ottou, Philippe Saas
Journal: Blood (2016)
R603: A New Low Dose Efficient Anti-CD20 Immunotherapy for CLL Patients ?
Authors: Magali Le Garff-Tavernier, Julie Decocq, Christophe de Romeuf, Jean-Luc Teillaud, Charles-Antoine Dutertre, Patrice Debre, Helene Merle-Beral, Vincent Vieillard
Journal: Blood (2008)
Comparative analysis of treatments, utilization, and survival benefit in HCC patients: A real-world analysis of SEER Medicare.
Authors: Fadia T. Shaya, Ian Michael Breunig, C. Daniel Mullins, Naimish B. Pandya, Viktor Chirikov, Brian S. Seal, Nader Hanna
Journal: Journal of Clinical Oncology (2012)

214 Background: We explore various treatments at all stages of Hepatocellular Carcinoma (HCC), in a SEER (Surveillance, Epidemiology and End-Results Program) Medicare population and assess their impact on HCC-specific and overall survival. Methods: Medicare enrollees, older than 65, with an initial diagnosis of a primary HCC between 2000-07 were followed up through end of 2009. Data are from the SEER and linked Medicare databases, with claims generated from Medicare parts A and B. Using multivariate Cox-proportional hazards models, we assessed overall and HCC-related mortality in relation to receipt of treatment/no treatment, adjusting for demographics, general health status (CCI), cancer stage and liver conditions. Results: Out of the 9054 HCC patients, older than 65, who did not get a liver transplant, 76% were Caucasian, 8% African American (AA), 63% male, and 37% got treatment [12% transarterial chemoembolization (TACE), 12% systemic chemotherapy, 1.5% selective internal radiation therapy (SIRT), 9% external beam radiation therapy (EBRT), 8% surgical resection and 9% ablative therapy]. Treatment was associated with a reduction of overall (HR=0.35, P= &lt;0.001) and HCC-related (0.33, &lt;0.001) mortality. HCC-related mortality was significantly reduced in those getting resection (0.38, &lt;0.001), ablation (0.59, &lt;0.001), TACE (0.76, &lt;0.001), EBRT (0.85, 0.017), or chemotherapy (0.85, 0.013). Significant reduction in overall mortality was seen with resection, ablation and TACE but not with chemotherapy, EBRT or SIRT. No particular treatment was associated with greater mortality reduction in early vs advanced stages. Patients with poor underlying health status (CCI&gt;1) had higher mortality (1.27, &lt;0.001). Alcohol related disease, Hep C, and moderate/severe liver dysfunction were not significantly associated with overall or HCC related mortality. Caucasians and non-African Americans had lower overall mortality (0.87, &lt;0.001). Conclusions: In HCC SEER Medicare patients, all treatments except SIRT were associated with a significant reduction in HCC related mortality. A limitation of this study is that, through the data, we cannot accurately depict the severity of the disease.
Utility of PCA3 urine assay in Japanese men undergoing prostate biopsy.
Authors: K. Okihara, A. Ochiai, K. Kamoi, T. Miki
Journal: Journal of Clinical Oncology (2011)

50 Background: Studies have shown the high specificity of PCA3 urine assay for biopsy detection of prostate cancer in European and American. We determined the diagnostic performance of PCA3 urine test in predicting prostate cancer in Japanese men. Methods: The study group included 261 men who underwent extended prostate biopsy at our institutions. 79 men of them had repeated biopsy. In all cases, race was Asian. Urine specimens were collected after digital rectal examination. On PROGENSA PCA3 assay, PCA3 score was calculated using PCA3 mRNA copy divided by PSA mRNA copy. PCA3 score was correlated with biopsy outcome and compared with serum PSA and free-total PSA. Results: 257 urine samples collected were successfully analyzed (i.e., the informative specimen rate was 98%). Biopsy revealed prostate cancer in 104 men (40%). There was no significant relationship between serum PSA and PCA3 score. PCA3 score in prostate cancer was significantly higher than that in negative (median 54.5 vs 17.0, p&lt;0.001). The probability of positive biopsy increased as PCA3 score increased. Using a PCA3 cutoff value of 35.0, sensitivity, specificity and diagnostic accuracy were 65%, 75% and 71%, respectively (p&lt;0.01). Area under the curve (AUC) for PCA3 score was 0.757 and AUC for serum PSA was 0.599 in all men. There was a significant difference in AUC between PCA3 score and serum PSA (p&lt;0.001). In men with serum PSA 4 to 10ng/ml, AUCs of PCA3 score, free-total PSA, and serum PSA were 0.759, 0.681, and 0.542, respectively. Conclusions: The specificity of PCA3 urine assay was high for detection of prostate cancer in Japanese men. PCA3 urine assay could improve the prediction for prostate cancer and help better decision making for prostate biopsy. No significant financial relationships to disclose.
The Clonal Architecture of CXCR4mutations in Waldenstrom's Macroglobulinemia Shows Highly Variable Subclonal Distribution, and Multiple Mutations within Individual Patients Indicative of Targeted Genomic Instability
Authors: Lian Xu, Zachary Hunter, Nicholas Tsakmaklis, Yang Cao, Guang Yang, Jie Chen, Xia Liu, Sandra Kanan, Jorge J Castillo, Yu-Tzu Tai, James L. Zehnder, Jennifer R. Brown, Ruben D. Carrasco, Ranjana H Advani, Kimon V. Argyropoulos, M. Lia Palomba, Enrica Morra, Alessandra Trojani, Antonino Greco, Alessandra Tedeschi, Marzia Varettoni, Luca Arcaini, Nikhil C. Munshi, Kenneth C Anderson, Steven P Treon
Journal: Blood (2015)
Constitutional symptoms in a young person
Authors: Sarah Hancox, David Howlett
Journal: BMJ (2016)

A 25 year old woman presented to her general practitioner with recent weight loss and night sweats. On examination she had palpable cervical lymphadenopathy, and a chest radiograph was obtained (fig 1⇓). What does this radiograph show? What is the differential diagnosis?



Fig 1  Chest radiograph



The chest radiograph (fig 2⇓) shows an anterior mediastinal mass with changes to aortopulmonary soft tissue (A and B) —consistent with mediastinal lymphadenopathy.



Fig 2  Chest radiograph showing mediastinal lymphadenopathy. A and B show nodal enlargement outside the normal mediastinal borders. …
Margin status and neoadjuvant chemoradiation in patients with borderline resectable pancreatic cancer.
Authors: Pavlos Papavasiliou, Jonathan R Piposar, Rodrigo Arrangoiz, Kathryn T Chen, Fang Zhu, Yun Shin Chun, John Parker Hoffman
Journal: Journal of Clinical Oncology (2012)

304 Background: The objective of this study was to examine the effect of margin status and neoadjuvant therapy in determining outcomes for borderline resectable (BLR) pancreatic cancer and how neoadjuvant chemoradiation impacts margin of resection. Methods: A retrospective chart review was conducted to identify patients who underwent resection for BLR pancreatic cancer based on the AHPBA/SSO/SSAT consensus definition. Outcomes including overall survival (OS) and disease free survival (DFS) were determined based on margin status, location of positive margin (artery, vein, or pancreas), and receipt of neoadjuvant chemoradiation. Results: One hundred and three patients who met the definition of BLR pancreatic cancer and underwent resection between April 1993 and July 2010 were reviewed. Mean age at diagnosis was 65 with a median follow up time of 19.7 months. Neoadjuvant chemoradiation was administered in 49.5% of patients. Twenty-five percent of patients underwent portal and/or superior mesenteric vein resection, and 7% hepatic artery resection. Microscopic positive margin rate was 54%. Median OS was 17.2 months for patients with positive margins versus 24.9 months for patients with negative margins (p=0.003). Median DFS was 13.1 months for patients with positive margins versus 18.6 months for patients with negative margins (p=0.001). There was no difference in OS or DFS for patients with positive margins based on location or number of positive margins. Of the patients who received neoadjuvant chemoradiation, 61.7% had a negative margin of resection versus a 38.3% negative margin of resection rate for patients who did not receive neoadjuvant chemoradiation (p=0.02). Among patients with a positive margin, there was no difference in OS or DFS with or without neoadjuvant chemoradiation. Conclusions: A positive margin of resection, irrespective of location or number, is associated with worse outcome in patients with BLR pancreatic cancer. The use of neoadjuvant chemoradiation is associated with higher rates of margin free resection.
Association of CD44s and CD44v6 expression on survival in malignant fibrious histiocytoma.
Authors: M. Peiper, W. Budach, W. T. Knoefel, C. Poremba, N. Stoecklein, M. Lehnhardt, P. A. Gerber, C. Matuschek, E. Boelke
Journal: Journal of Clinical Oncology (2011)

e20504 Background: New prognostic markers are being searched to determine the value of adjuvant and/or palliative treatment in soft tissue sarcomas (STS). Several studies have shown, that CD44 expression is associated with a better outcome in certain cancers, such as bladder tumors. The aim of this study was to evaluate the expression of CD44 in STS of the adult and to determine whether CD44 expression correlates with the clinical outcome Methods: We examined the clinical outcome of 34 adult MFH patients (19 males and 15 females, average age 62 years, median 63 years, ranged from 38 to 88 years) who underwent curative treatment for STS. The majority of patients received adjuvant radiotherapy (n = 25). No patient received initial adjuvant chemotherapy. The expressions of CD44, CD44 isoforms and the reference genes beta-actin and beta-microglobulin were analyzed by quantitative real-time PCR. For relative quantification and to normalize the amount of the CD44 product and the CD44 isoform products, the delta-CT method using the expression of the reference genes beta-actin or beta-microglobulin was used. Results: High CD44s expression levels were positively correlated with a lower tumor-related death (P < 0.05, log-rank test 3,85). Conversely, high expression levels of hCD44 were negatively correlated with a tumor-related death with a median survival of 43 months as compared to 61 months in patients with low expression levels. In the three analyzed variants of CD44, high expression levels of CD44v6 and CD44v8 correlated negatively with the tumor-related survival. Multivariate prognostic risk factors based on the Cox proportional-hazards regression model included three variables: CD44s (P = 0.006), CD44v6 (P = 0.003) as well as resection quality (P = 0.03) were all identified as significant parameters of survival. Conclusions: Low expression levels of CD44s as well as high expression levels of CD44v6 and CD44v8 correlate with poor outcome.
Prognostic classification of ipsilateral breast tumor recurrence (IBTR).
Authors: F. G. Eladoumikdachi, M. Jones, A. Shidfar, I. B. Helenowski, J. M. Franz, D. Scholtens, M. E. Sullivan, K. P. Bethke, N. M. Hansen, J. S. Jeruss, S. A. Khan
Journal: Journal of Clinical Oncology (2011)

137 Background: IBTR after breast conservation encompasses true recurrence (TR) and new primary cancer (NP). No clear criteria distinguish TR from NP, but there is agreement that NP tumors have better outcomes than TR. Prior studies have used distance of IBTR from index cancer (IC), time to IBTR, histological, immunohistochemical (IHC) and genetic differences, but all data are not often available. We have examined IBTR patterns with the goal of identifying the simplest, most robust determinants of outcomes following IBTR. Methods: We reviewed records of breast cancer patients diagnosed with IBTR at the Lynn Sage Breast Center from 8/1992 to 6/2010. Data for the IBTR and IC were reviewed for histology, IHC, location, time between IC and IBTR, follow-up status, and cause of death. Parameters were scored as 1 if IBTR and IC were similar, and 0 if different (location=1 if ≤3cm; IHC=1 if hormone receptors and HER2 similar; interval=1 if ≤ 4 years). Univariate and multivariate proportional hazard models were used to determine impact on overall survival (OS), disease-specific survival (DSS), recurrence-free survival (RFS), distant recurrence free survival (DRFS) and local recurrence (LR). The multivariate model included significant univariate parameters. Results: We identified 161 patients with IBTR and complete data on ≥3 parameters; post-IBTR median follow up was 25 months. Data were missing on location in 13%, histology in 9%, IHC in 26%, and time interval in 0%. In univariate analysis, short interval to IBTR significantly decreased OS (HR 2.56, p=0.04), DSS (HR 4.31, p=0.009), RFS (HR 2.25, p=0.01), DRFS (HR 2.53, p=0.02), LR (HR 2.28, p=0.02); close location of IBTR decreased OS (HR 2.68, p=0.04). Histology and receptor status had no significant impact on the outcomes. Multivariate analysis included time and location, time ≤ 4 years was shown to decrease DSS (HR 4.00, p= 0.04), RFS (HR 2.32, p=0.03) and LR (HR 2.41, p=0.03). Conclusions: A short time interval between IC and IBTR is the most important prognostic parameter; location of IBTR within 3 cm of the IC also increases HR of subsequent events. These are the most easily available parameters when evaluating patients with IBTR, and therefore the most useful for distinction of TR versus new primary.
The Relationship Between Chromosomally Abnormal Hematopoiesis and the JAK2V617F Allele Burden in Patients (pts) with Ph-Negative Chronic Myeloproliferative Disorders (Ph-neg MPD)
Authors: Xialoli Wang, Amanda Leblanc, Steven Gruenstein, Mingjiang Xu, Nathaniel Wisch, Ronald Hoffman, Vesna Najfeld
Journal: Blood (2008)
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) evaluation of preoperative therapy for extremity soft tissue sarcomas (STS).
Authors: J. M. Meyer, K. S. Perlewitz, S. L. Hemmingson, J. B. Hayden, A. Hung, A. Mansoor, M. L. Holtorf, W. J. Woodward, C. S. Springer, W. Huang, C. W. Ryan
Journal: Journal of Clinical Oncology (2011)

10098 Backgound:DCE-MRI detects changes in tumor perfusion and may be useful in assessing response to therapy. The “Shutter-Speed” Model (SSM) for DCE-MRI pharmacokinetic (PK) analysis may be more sensitive than the Standard (Tofts) Model (SM) as it admits the fact that equilibrium transcytolemmal water exchange is not infinitely fast. We performed a feasibility study of SSM DCE-MRI in patients receiving preoperative therapy for STS, including assessment of a new DCE-MRI PK parameter ΔKtrans [≡Ktrans (SSM) – Ktrans (SM)], a measure of the finite water exchange effects on DCE-MRI PK analysis. Methods: Subjects with >5 cm, grade 2-3, extremity/body wall STS received preoperative sorafenib (S) + epirubicin/ifosfamide (E/I) or E/I alone. All patients received 28 Gy radiation in 8 fractions. DCE-MRI was performed at baseline [time point zero (TP0)], after 2 weeks S or E/I (TP1), and after completion of preoperative therapy (TP2). The SM and SSM were used for PK modeling on tumor region of interest (ROI) and pixel-by-pixel basis. Percent changes in PK biomarkers were calculated at TP1 and TP2 relative to TP0. Percent histopathologic necrosis was estimated in the resection specimen. Results: 6 subjects were enrolled. TP0 Ktrans was greater using SMM than with SM (mean 0.074 vs 0.067, p=0.16). 4 subjects completed all 3 DCE-MRIs; one tumor with >95% necrosis after therapy had a greater decrease in ΔKtrans [tumor ROI or histographic median (HM)] at TP1 compared to those with <95% necrosis (Table). RECIST and WHO measures of tumor size change at TP1 were indiscriminate in relation to necrosis percentage. Conclusions: SSM DCE-MRI is a feasible modality to assess therapeutic response of STS. ΔKtrans may be a sensitive biomarker for detecting early therapy-induced tumor vascular changes and potentially provide early prediction of response to therapy. Subject Treatment % Necrosis Histology ΔKtrans ROIa ΔKtrans HMa ΔKtrans ROIb ΔKtrans HMb 1 S + E/I >95 MRCL -66 -117 -97 -140 2 S + E/I 85 MRCL -35 -90 -26 -91 3 E/I 40-50 Pleomorphic — — — — 4 S + E/I 10-20 Pleomorphic -21 8 -35 -94 5 E/I 50 Myxofibrosarcoma -9 6 -43 -90 6 S + E/I 95 Pleomorphic — — — — a Change from TP0 to TP1 (min-1). b Change from TP0 to TP2 (min-1).
Preliminary Report of Microcephaly Potentially Associated with Zika Virus Infection During Pregnancy — Colombia, January–November 2016
Authors: Esther Liliana Cuevas, Van T. Tong, Nathaly Rozo, Diana Valencia, Oscar Pacheco, Suzanne M. Gilboa, Marcela Mercado, Christina M. Renquist, Maritza González, Elizabeth C. Ailes, Carolina Duarte, Valerie Godoshian, Christina L. Sancken, Angelica Maria Rico Turca, Dinorah L. Calles, Martha Ayala, Paula Morgan, Erika Natalia Tolosa Perez, Hernan Quijada Bonilla, Ruben Caceres Gomez, Ana Carolina Estupiñan, Maria Luz Gunturiz, Dana Meaney-Delman, Denise J. Jamieson, Margaret A. Honein, Martha Lucia Ospina Martínez
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

In Colombia, approximately 105,000 suspected cases of Zika virus disease (diagnosed based on clinical symptoms, regardless of laboratory confirmation) were reported during August 9, 2015-November 12, 2016, including nearly 20,000 in pregnant women (1,2). Zika virus infection during pregnancy is a known cause of microcephaly and serious congenital brain abnormalities and has been associated with other birth defects related to central nervous system damage (3). Colombia's Instituto Nacional de Salud (INS) maintains national surveillance for birth defects, including microcephaly and other central nervous system defects. This report provides preliminary information on cases of congenital microcephaly identified in Colombia during epidemiologic weeks 5-45 (January 31-November 12) in 2016. During this period, 476 cases of microcephaly were reported, compared with 110 cases reported during the same period in 2015. The temporal association between reported Zika virus infections and the occurrence of microcephaly, with the peak number of reported microcephaly cases occurring approximately 24 weeks after the peak of the Zika virus disease outbreak, provides evidence suggesting that the period of highest risk is during the first trimester of pregnancy and early in the second trimester of pregnancy. Microcephaly prevalence increased more than fourfold overall during the study period, from 2.1 per 10,000 live births in 2015 to 9.6 in 2016. Ongoing population-based birth defects surveillance is essential for monitoring the impact of Zika virus infection during pregnancy on birth defects prevalence and measuring the success in preventing Zika virus infection and its consequences, including microcephaly.
Low-dose versus standard-dose gemcitabine infusion and cisplatin for patients with advanced bladder cancer: A randomized phase II trial: An update.
Authors: Rasha Mohamed Haggag, Kamel Farag, Fouad Abu-Taleb, Sameh Shamaa, Abdel-Rahman Zekri, Tarek ELBolkainy, Hussein Mustafa Khaled
Journal: Journal of Clinical Oncology (2013)

4537 Background: Bladder carcinoma is still one of the foremost oncologic problems in Egypt. In previous single-arm and double-arm phase II studies, prolonged infusion of low dose gemcitabine and cisplatin proved to be an effective treatment for such patients with advanced disease. Methods: To compare efficacy and safety of both prolonged infusion and standard gemcitabine-cisplatin combination, we updated the data and duplicated the number of patients of our previously published phase II randomized study to 120 untreated patients with stage III/IV bladder cancer. Patients were randomized to receive either gemcitabine (250 mg/m 2 ) 6-hour infusion on days 1 and 8, and cisplatin (70 mg/ m 2 ) on day 2 every 21-day cycle (Arm1) or gemcitabine (1,250 mg/ m 2 ) 30-min infusion on days 1 and 8, and cisplatin (70 mg/ m 2 ) on day 2 every 21-day cycle (Arm 2). Results: The 92 males and 28 females had a median age of 62 years (range 40-85 years). A total of 87 patients had transitional cell, 28 had squamous cell, and 5 had undifferentiated cell carcinoma. Among the 105 evaluable patients (52patients in arm1 and 53patients in arm 2), complete response rate was achieved in 13.5% (7/52 patients of arm 1) and 5.7% (3/53 patients of arm 2). Eighteen patients in arm 1 (34.6%) and 17 patients (32.1%) in arm 2 had partial response on therapy. Thus the overall response rate of patients in arm1 and arm 2 was 48% (25/52 patients) and 37.7% (20/53patients), respectively (p = 0.26). No significant difference in median time to disease progression (26 months versus 24 months, p =0.4), median survival (12 months versus 16 months, p =0.8), and 1-year survival (49.9 % versus 54.7%, p = 0.8) was detected between arms 1 and 2, respectively. No treatment- related deaths occurred. Main hematologic and nonhematologic toxicities were similar in both arms with no statistically signiﬁcant differences. Conclusions: In the treatment of advanced bladder cancer, gemcitabine in low dose and prolonged infusion in combination with cisplatin is not inferior to high-dose short infusion gemcitabine and cisplatin in terms of overall survival, time to disease progression, and response rates with favorable toxicity profile and less financial costs.